

With added DNA markers to better risk stratify hematuria patients



A next generation
Cxbladder test
with enhanced
performance!


Cxbladder Triage Plus is a non-invasive genomic test that employs a novel combination of mRNA and DNA markers to extend best in class performance.

Optimize your clinical practice, allowing physicians to focus on high risk patients and procedures.

Triage Plus enhances risk stratification, reducing unnecessary cystoscopies in patients with a low probability of urothelial cancer, while prioritizing those who need immediate care.

Give patients the best experience possible.

Triage Plus spares patients with a low probability of disease the discomfort, anxiety and risks of an invasive procedure.



Simplified ordering

- One test for microhematuria.
- Requires a urine sample only.
No additional patient factors are necessary.

* 98% specificity and 75% PPV when higher 0.54 test report cut point used.

Diagnostic Performance of Cxbladder Triage Plus for the Identification and Stratification of Patients at Risk for Urothelial Carcinoma: The Multicenter, Prospective, Observational DRIVE Study.

Savage et al. (2025) Urologic Oncology, S1078-1439(25)00405-3

Summary of key clinical outcomes:

- Triage Plus had higher specificity and sensitivity than first-generation Cxbladder assays.
- The test reduced the number of hematuria patients who required further evaluation compared to American Urological Association (AUA) risk stratification.
- Similar performance was observed in patients with either gross or microscopic hematuria.
- 171/615 patients tested positive by Triage Plus and 45/48 tumors were detected.

* Veterans Affairs provides medical care for ex-service men and women.

Conclusion:

The test informs and refines beyond traditional hematuria risk classification systems, further defining patients who truly need a cystoscopy and those who could defer further evaluation.

Spend less time looking for UC that isn't there and more time with those who need it the most. Maximize the value of your time and clinical resources for the most patient benefit.


With added DNA markers to better risk stratify hematuria patients

-  Cxbladder Triage Plus is a next generation Cxbladder test that combines an analysis of 5 mRNA biomarkers with DNA markers (TERT, FGFR3) to provide enhanced clinical utility.
-  Triage Plus extends best in class performance from both Cxbladder Triage and Detect, increasing the rate of UC rule out in microhematuria patients with a low probability of disease.
-  Triage Plus improves the identification of high-risk patients with a significantly higher specificity and PPV at the higher end, while retaining the high NPV and rule out rate.

Test Results: Cxbladder Triage Plus score

0.05

95% CI (0.02–0.10)



- 1**
- **84% of patients resulted with a LOW probability score.**
 - A LOW probability score has an NPV of 99.4%.
 - **Patients in this zone have a 0.6% probability of having UC.**

- 2**
- 9.5% of patients resulted with an INTERMEDIATE probability score.
 - Patients in this zone have a 27.7% probability of having UC.

- 3**
- **6.4% of patients resulted with a HIGH probability score.**
 - A HIGH probability score has a PPV of 74.6%.
 - **Patients in this zone have a 74.6% probability of having UC.**

- The performance characteristics referenced above are from the validation cohort using three clinical data sets from two ethnically diverse populations (USA and Singapore) totaling 987 patients (gross hematuria: n=605, microhematuria: n=382)
- Cxbladder Triage Plus testing requires 4.5mLs of urine to be completed. No patient clinical characteristics are necessary.

Contact us

Email: info@cxbladder.com

Phone: 1-855-CXBLADR (1-855-292-5237)

Learn more

Visit us online at www.cxbladder.com